177 related articles for article (PubMed ID: 36335460)
21. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of mepolizumab in patients with severe eosinophilic asthma: In a real life study].
Bulut İ; Yegin Katran Z; Yavuz D; Yıldız AB; Yakut T; Örçen C; Mersin SS
Tuberk Toraks; 2023 Jun; 71(2):148-155. PubMed ID: 37345397
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
25. Real-life cost-effectiveness of benralizumab in patients with severe asthma.
Padilla-Galo A; García-Ruiz AJ; Levy Abitbol RC; Olveira C; Rivas-Ruiz F; García-Agua Soler N; Pérez Morales M; Valencia Azcona B; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
Respir Res; 2021 May; 22(1):163. PubMed ID: 34044819
[TBL] [Abstract][Full Text] [Related]
26. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
Abdo M; Watz H; Veith V; Kirsten AM; Biller H; Pedersen F; von Mutius E; Kopp MV; Hansen G; Waschki B; Rabe KF; Trinkmann F; Bahmer T
Respir Res; 2020 Oct; 21(1):278. PubMed ID: 33087134
[TBL] [Abstract][Full Text] [Related]
27. Effects of Benralizumab on Three-Dimensional Computed Tomography Analysis in Severe Eosinophilic Asthma.
Tsubokawa F; Koya T; Murai Y; Tanaka K; Tsutsui Y; Naramoto S; Sakai N; Aoki A; Shima K; Kimura Y; Watanabe S; Hasegawa T; Kikuchi T
Int Arch Allergy Immunol; 2023; 184(3):243-251. PubMed ID: 36470233
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation.
Eger K; Kroes JA; Ten Brinke A; Bel EH
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1194-1200. PubMed ID: 33069885
[TBL] [Abstract][Full Text] [Related]
29. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
30. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
31. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Gerday S; Graff S; Moermans C; Guissard F; Paulus V; Henket M; Louis R; Schleich F
Thorax; 2023 Nov; 78(11):1138-1141. PubMed ID: 37657926
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.
Di Bona D; Crimi C; D'Uggento AM; Benfante A; Caiaffa MF; Calabrese C; Campisi R; Carpagnano GE; Ciotta D; D'Amato M; Pelaia C; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Ribecco N; Spadaro G; Valenti G; Vatrella A; Crimi N; Macchia L
Clin Exp Allergy; 2022 Feb; 52(2):312-323. PubMed ID: 34608696
[TBL] [Abstract][Full Text] [Related]
33. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
[TBL] [Abstract][Full Text] [Related]
34. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
[TBL] [Abstract][Full Text] [Related]
35. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.
Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ
Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980
[TBL] [Abstract][Full Text] [Related]
36. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
37. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
38. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Brooks L; Olsson RF; Martin UJ; Goldman M;
J Allergy Clin Immunol; 2021 Jul; 148(1):266-271.e2. PubMed ID: 33609624
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis.
Bagnasco D; Brussino L; Bonavia M; Calzolari E; Caminati M; Caruso C; D'Amato M; De Ferrari L; Di Marco F; Imeri G; Di Bona D; Gilardenghi A; Guida G; Lombardi C; Milanese M; Nicolini A; Riccio AM; Rolla G; Santus P; Senna G; Passalacqua G
Respir Med; 2020 Sep; 171():106080. PubMed ID: 32917354
[TBL] [Abstract][Full Text] [Related]
40. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients.
Watanabe H; Shirai T; Hirai K; Akamatsu T; Nakayasu H; Tamura K; Masuda T; Takahashi S; Tanaka Y; Kishimoto Y; Oishi K; Saigusa M; Yamamoto A; Morita S; Asada K
J Asthma; 2022 Sep; 59(9):1796-1804. PubMed ID: 34348060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
